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Abstract 37 
Aims. A proof-of-concept study to explore whether DNA methylation at first diagnosis 38 
is associated with response to disease-modifying antirheumatic drugs (DMARDs) in 39 
patients with early rheumatoid arthritis (RA). 40 
Patients & Methods. DNA methylation was quantified in T-lymphocytes from 46 41 
treatment-naïve patients using HumanMethylation450 BeadChips. Treatment response 42 
was determined at six months using the EULAR response criteria. 43 
Results. Initial filtering identified 21 CpGs that were differentially methylated between 44 
responders and non-responders. After conservative adjustment for multiple testing, six 45 
sites remained statistically significant, of which four showed high sensitivity and/or 46 
specificity (≥75%) for response to treatment. Moreover, methylation at two sites in 47 
combination was the strongest factor associated with response (80.0% sensitivity, 48 
90.9% specificity, AUC 0.85).  49 
Conclusions. DNA methylation at diagnosis is associated with DMARD treatment 50 
response in early RA. 51 
  52 
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Introduction 53 
Rheumatoid arthritis (RA) is a chronic inflammatory joint disease of autoimmune origin 54 
that affects 0.5–1.0% of the adult population [1, 2]. Treatment of patients with centres 55 
on the use of a variety of synthetic disease-modifying antirheumatic drugs (DMARDs). 56 
Methotrexate is the first-line DMARD of choice for the treatment and management of 57 
RA, prescribed as monotherapy or in combination with other DMARDs. Although these 58 
agents are efficacious for the treatment of RA [3-5], clinically meaningful responses are 59 
not observed in all patients and a significant proportion remain refractory to treatment. 60 
 61 
A substantial body of literature supports an important role for epigenetic dysregulation, 62 
including of DNA methylation, in the pathogenesis of RA [reviewed in 6-8]. Evidence 63 
also suggests that disease modifying agents such as methotrexate may influence DNA 64 
methylation [9, 10]. Moreover, methylation status as a potential biomarker associated 65 
with response to therapy has been demonstrated in other conditions [11] and proposed 66 
for use in RA by several investigators [12, 13]. DNA is methylated through enzymatic 67 
conversion of cytosine to methylcytosine; this occurring almost invariably at cytosine-68 
phosphate-guanine sites (CpGs). In the context of promoter-associated sites, 69 
methylation is associated with transcriptional repression and gene silencing [14]. In RA, 70 
alterations to the DNA methylome are apparent in multiple cell types important in the 71 
disease process, including peripheral blood-derived mononuclear cells, lymphocytes and 72 
joint-derived fibroblasts. Recently, we were the first to define disease-associated 73 
methylation changes that were distinct to individual T- and B-lymphocyte populations 74 
[15]. Moreover, we reported methylation differences in these lymphocyte populations in 75 
treatment-naïve patients at first RA diagnosis [16]. Whilst providing evidence for a role 76 
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in the development of the disease, our findings support DNA methylation profiling at 77 
diagnosis as a potential source of biomarkers for response to treatment in RA. 78 
 79 
It is clear that the ability to identify which patients will respond to treatment offers 80 
considerable benefits for the management of RA. For example, it would (i) facilitate 81 
rapid dose-escalation and reduce time to effective response in those likely to be poor 82 
responders to traditional regimens, and (ii) avoid unwanted side-effects in those likely 83 
to show an effective response to lower doses or monotherapy. These benefits are all the 84 
more important given evidence that response to first treatment with disease-modifying 85 
agents is strongly associated with long-term outcome in these patients [17]. The search 86 
for biomarkers associated with response has encompassed demographic and clinical 87 
factors as well as genetic associations and expression profiling of proinflammatory and 88 
other mediators [18-20]. However, no single factor or combination of factors have thus 89 
far proven to be accurate and reliable in determining which patients will respond to 90 
DMARD therapy. 91 
 92 
Our aim therefore, in this proof-of-concept study, was to determine whether genome-93 
wide DNA methylation profiles at first diagnosis are associated with response to 94 
treatment with conventional DMARDs  (as determined by improvement in disease 95 
activity using the validated European League Against Rheumatism (EULAR) response 96 
criteria) in a typical population of newly-diagnosed, treatment-naïve patients with RA. 97 
As in our previous work, we examined methylation in purified T-lymphocyte 98 
populations, cells that are instrumental in the disease process and chronic inflammation 99 
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[21], and for which relationships with disease activity have recently been described [22-100 
24].   101 
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Patients and Methods 102 
Study population 103 
A prospective cohort of 46 Caucasian patients attending the early synovitis clinic at the 104 
Haywood Rheumatology Centre in Stoke-on-Trent, UK, and presenting with 105 
symptomatic inflammatory arthritis suspected to be RA was recruited. All patients were 106 
subsequently classified as having RA, according to the 2010 ACR/EULAR 107 
classification criteria, by a consultant rheumatologist [25]. No patients had been treated 108 
with DMARDs or biological agents at the time of recruitment. Clinical data collected at 109 
baseline included disease activity, erythrocyte sedimentation rate (ESR), rheumatoid 110 
factor (RF) and anti-citrullinated peptide antibodies (ACPA). Demographic and clinical 111 
characteristics are presented in Table 1. At diagnosis with RA, all patients began 112 
treatment with one or more DMARDs (methotrexate, hydroxychloroquine, and 113 
sulphasalazine) and the majority received parenteral corticosteroids, solely for the 114 
clinical management of RA and as directed by a consultant rheumatologist. Patients 115 
were followed for six-months and remained on treatment throughout. The study was 116 
approved by the East Midlands (Derby) Research Ethics Committee. All patients 117 
provided written informed consent. 118 
 119 
Disease activity was determined at recruitment (prior to initiation of DMARD therapy) 120 
and after three and six months of treatment using the disease activity score with 28-joint 121 
counts (DAS28) [26], though data at three months was excluded from further analysis 122 
due to the known short-term effect of corticosteroid treatment on DAS28 scores. 123 
DAS28 scores range from 0-10: a score >5.1 indicates high disease activity while one of 124 
≤3.2 denotes low disease activity. Response to treatment was determined at six months 125 
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according to the DAS28-based EULAR response criteria [26-28], which evaluate 126 
response in patients with RA based on a composite categorization incorporating both 127 
change in DAS28 from baseline (∆DAS28) and final absolute DAS28 score. 128 
Specifically, these criteria classify response as ‘good’ (∆DAS28 >1.2, current DAS28 129 
≤3.2), ‘moderate’ (∆DAS28 >1.2, current DAS28 >3.2, or ∆DAS28 >0.6–1.2, current 130 
DAS28 ≤5.1) and ‘no’ (∆DAS28 ≤0.6, or ∆DAS28 >0.6–1.2, current DAS28 >5.1) [28]. 131 
According to these criteria, responders were defined as patients with a ‘good’ or 132 
‘moderate’ response to treatment, and non-responders as patients with ‘no’ response to 133 
treatment. 134 
 135 
Isolation of T-lymphocytes 136 
Fresh peripheral blood samples (35 ml, EDTA) were collected from each patient at 137 
baseline, prior to the initiation of treatment. CD3+ T-lymphocytes were isolated from 138 
mononuclear cell preparations using positive selection with magnetic microbeads 139 
(MACS® Separation System; Miltenyi Biotec). We have previously shown this method 140 
to yield high-purity T-lymphocyte populations (mean ≥ 99%) in RA patients [15]. 141 
Genomic DNA was extracted using an AllPrep DNA/RNA/miRNA Universal kit 142 
(Qiagen) and stored at -20°C prior to use. 143 
 144 
Genome-wide DNA methylation profiling 145 
DNA methylation was quantified at >480,000 CpG sites using the 146 
HumanMethylation450 BeadChip (Illumina Inc.; hereafter referred to as ‘array’). 147 
Details of array design and coverage have been described elsewhere [29]. Genomic 148 
DNA samples (n = 46) were treated with sodium bisulfite using an EZ DNA 149 
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Methylation Kit (Zymo Research) and subsequently were hybridized to arrays according 150 
to manufacturer recommended protocols, as previously described (performed by 151 
Hologic Tepnel Pharma Services, Manchester, UK) [30]. All samples passed stringent 152 
internal array quality control, including sample-independent (e.g. staining, 153 
hybridization) and sample-dependent (e.g. bisulfite conversion) controls. Methylation at 154 
individual CpG sites is reported as a β-value ranging from 0 to 1 (unmethylated to fully 155 
methylated, respectively) [29]. 156 
 157 
Sodium bisulfite Pyrosequencing 158 
Array candidates were independently validated by bisulfite Pyrosequencing using a 159 
PyroMark Q24 instrument and analysis software (Qiagen), as we have previously 160 
described [15, 30]. Briefly, fresh genomic DNA aliquots were sodium bisulfite-161 
converted and amplified using whole genome amplification [30, 31]. Thereafter, 162 
Touchdown PCR [32, 33] was used to prepare PCR amplicons containing CpGs of 163 
interest. Assay details are provided in Supplementary Table 1. 164 
 165 
Data analysis 166 
Array data (idat files) were processed and analyzed using the Bioconductor package 167 
Minfi [34]. We removed from analysis all CpGs with a detection p-value >0.01 in any 168 
one or more of the 46 samples and all probes targeting sites on the X and Y 169 
chromosomes (a total of 12,295 CpGs). Data were normalized by Subset-quantile 170 
Within Array Normalization (SWAN), as described by Maksimovic et al. [35], and 171 
multi-dimensional scaling plots were examined to confirm appropriate adjustment for 172 
potential confounding due to batch effects (processing date, array position and slide). 173 
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 174 
To identify methylation differences associated with treatment response, patients were 175 
stratified into responders and non-responders. CpGs showing altered methylation 176 
between the two groups were identified using the ‘dmpFinder’ function in Minfi. This 177 
function performs an F-test to compare groups and was used with logit-transformed β-178 
values (M-values), as recommended by Du et al. [36]. P-values <0.05 were considered 179 
statistically significant and, together with a mean β-value difference ≥0.1 between the 180 
groups, were used as an initial screening tool to identify sites displaying differential 181 
methylation. Two further filtering steps were subsequently applied to identify 182 
differentially methylated CpGs as those sites where: 1) at least two-thirds of non-183 
responders showed a β-value difference ≥0.1 relative to the responder mean; and 2) at 184 
least two-thirds of responders displayed a β-value equal to or in excess of the responder 185 
mean. Filtering criteria are summarized in Figure 1. We then applied a Bonferroni 186 
adjustment at stage 5, based on comparisons conducted using the final 21 CpGs 187 
identified. 188 
 189 
The McNemar test was used to examine the incidence of patients with moderate/high 190 
disease activity between baseline and six-months. The association of baseline 191 
methylation status with treatment response was determined by calculating sensitivity, 192 
specificity, positive predictive value (PPV) and negative predictive value (NPV), and by 193 
examining receiver operating characteristic (ROC) area under the curve (AUC) plots. 194 
ROC curves were constructed based on logistic regression analysis with response to 195 
treatment categorised as no response versus moderate/good response as described 196 
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above. Analyses were performed using Stata 12.0 (Intercooled; Stata Corporation, TX, 197 
USA) and considering p-values <0.05 as statistically significant.  198 
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Results 199 
Characteristics of the patients 200 
Table 1 summarizes the demographic and clinical characteristics for the RA patients at 201 
recruitment. Most patients (43/46, 93.5%) started treatment with MTX, either as 202 
monotherapy or in combination with other DMARDs. The majority of patients (33/46, 203 
71.7%) remained on their indicated starting DMARD regimen throughout the course of 204 
the study. Of the remaining patients, all but two introduced or discontinued a single 205 
DMARD on one occasion during the six-month follow-up period. 206 
 207 
Disease activity and treatment response 208 
Moderate or high disease activity (DAS28 >3.2) was present in 43/46 (93.5%) patients 209 
at recruitment (three patients had low disease activity, with DAS28 scores of 2.27, 2.66 210 
and 3.18). After six-months of treatment, 28/46 (60.9%) patients had moderate/high 211 
disease activity (p <0.001 vs. baseline, McNemar test), with approximately two-thirds 212 
(63.0%) achieving an improvement in DAS28 ≥1.2. Classifying response by the 213 
EULAR response criteria, the number of patients achieving a good, moderate and no 214 
response to treatment at six-months was 16 (34.8%), 19 (41.3%), and 11 (23.9%), 215 
respectively. On this basis, 76.1% (35/46) of patients were classified as responders and 216 
the remainder as non-responders. Details of baseline characteristics and six-month 217 
treatment regimens for the two groups are presented in Supplementary Table 2.  218 
 219 
Relationship between DNA methylation and treatment response 220 
Use of the robust filtering steps described in the Methods section and shown in Figure 1 221 
identified 269 CpGs with a statistically significant difference in mean methylation β-222 
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value ≥0.1 between responders and non-responders. Moreover, for a subset of 21 sites, 223 
methylation differences were present in at least two-thirds of the individual patients 224 
within each group (full annotation for these 21 sites is provided in Supplementary 225 
Table 3). The majority of these sites were hypermethylated in responders (16/21, 226 
76.2%), were linked with a gene (15/21, 71.4%) and were associated with a CpG island 227 
and/or the surrounding shores/shelves (13/21, 61.9%). 228 
 229 
To refine these sites further, we applied a conservative Bonferroni adjustment for 230 
multiple testing, based on the 21 comparisons undertaken. This revealed six CpGs for 231 
which the methylation differences between responders and non-responders remained 232 
statistically significant (padj <0.05; Supplementary Table 3). For each of these six 233 
CpGs, we plotted methylation against treatment response to determine a percentage 234 
methylation cut-off that in each case provided the greatest discrimination between 235 
patients that responded to treatment and those that did not. Examples of two 236 
differentially methylated CpGs are presented in Figure 2. We also calculated the 237 
corresponding sensitivity and specificity for each site to assess the association of 238 
methylation status with response. Using this approach, and as shown in Table 2, four 239 
sites were identified with a sensitivity and/or specificity ≥75% for discrimination 240 
between responders and non-responders. Most notably, hypermethylation of CpG-2 and 241 
hypomethylation of CpG-3 (shown in Figure 2 and validated by Pyrosequencing in 242 
Supplementary Figure 1) each demonstrated a sensitivity and PPV of approximately 243 
90%, although the corresponding specificity and NPV were lower (63.6% and 70.0%, 244 
and 63.6% and 63.6%, for CpG-2 and CpG-3, respectively). Using ROC curve analysis 245 
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to further evaluate the association with response, CpG-2 and CpG-3 also demonstrated 246 
the highest AUC values (0.78 and 0.76, respectively). 247 
 248 
Combinations of CpGs associated with treatment response 249 
Focusing on the four sites identified above, we next examined the ability to discriminate 250 
between responders and non-responders for each of the six possible pairs of sites. The 251 
combination of hypermethylation of CpG-2 and hypomethylation of CpG-3 252 
demonstrated the best overall performance with a sensitivity of 80.0% and specificity of 253 
90.9% (Table 2). As shown in Figure 3, 28 of 29 patients with this combination were 254 
responders (14 good and 14 moderate response; right chart, Figure 3). In contrast, all 255 
four patients failing to satisfy either cut-off were non-responders (left chart, Figure 3). 256 
The strength of the association of the CpG-2 + CpG-3 combination with response was 257 
also reflected in a ROC AUC of 0.85 (95% confidence interval [CI] 0.71, 0.94).  258 
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Discussion 259 
This is the first study to examine the link between DNA methylation and first-line 260 
treatment response in RA. Using a prospective cohort of patients recruited at first 261 
diagnosis and prior to the initiation of treatment, our data indicate that baseline DNA 262 
methylation levels for a discrete subset of sites are significantly associated with 263 
response to treatment with disease-modifying agents. The methylation status at two 264 
specific sites assessed in combination, and which independently were associated with 265 
response, proved to be the strongest factor associated with treatment response.  266 
 267 
Since early, effective intervention in RA reduces disease activity and inflammation, and 268 
improves long-term outcome [37-40], identification of baseline factors associated with 269 
treatment response has been a priority. However, examination of a broad range of 270 
clinical, molecular and genetic factors has not produced definitive biomarkers [18, 19]. 271 
Our findings now provide the first evidence that epigenetic profiling, in this case of 272 
DNA methylation, may have significant value in identifying which patients with RA 273 
may respond to first-line DMARD treatment. Furthermore, DNA methylation is an 274 
attractive biomarker since it is typically stable over time, is minimally affected by short-275 
term stimuli and is readily measured [12]. The potential utility of methylation profiling 276 
is further supported by a very recently reported association between differential DNA 277 
methylation and response to second-line anti-TNF therapy in RA [41]. 278 
 279 
We were unable to formally examine the independence of the CpG-2 + CpG-3 280 
association with treatment response in this proof-of-concept study. However, a 281 
preliminary assessment using our data suggested that it was independent of baseline 282 
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clinical variables including disease activity, autoantibodies and systemic inflammatory 283 
markers, which individually did not appear to be associated with response. This would 284 
be in agreement with the main body of literature, which indicates that ESR, RF and 285 
ACPA are not independently associated with response to methotrexate and/or other 286 
DMARDs [reviewed in 18]. Although not reported by all studies [42], evidence does 287 
indicate that male sex is associated with a better response to methotrexate [43-45]. Our 288 
data suggest a possible trend towards better response in males (p <0.1), which may 289 
reflect treatment with methotrexate for over 90% of the patients studied. 290 
 291 
The CpG-2 + CpG-3 combination, which we identified as the strongest independent 292 
factor associated with treatment response, comprises sites in ADAMTSL2 (CpG-2), a 293 
disintegrin and metalloproteinase with thrombospondin motif-like protein, and in 294 
BTN3A2 (CpG-3), a butyrophilin family member. Although the function of 295 
ADAMTSL2 has not been fully determined, evidence supports a role in the regulation 296 
of transforming growth factor-β (TGF-β) [46]. TGF-β is a pleiotropic cytokine with 297 
important immunoregulatory functions [47, 48], which is implicated in RA synovial 298 
pathology [49]. Butyrophilins are transmembrane proteins that share structural 299 
similarities with B7 co-stimulatory molecules and are emerging as novel regulators of 300 
T-lymphocyte function and immune responses [50, 51]. 301 
 302 
We focused on DNA methylation factors associated with response in the context of 303 
DMARD treatment strategies that reflected standard clinical practice. Both responder 304 
and non-responder groups included patients receiving methotrexate monotherapy and 305 
patients receiving combination therapy, the proportions of which were not significantly 306 
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different either at baseline or at six-months follow-up (Supplementary Table 2). 307 
Importantly, methylation at two CpGs in combination was strongly associated with 308 
treatment response despite the limited variation in treatment regimens, supporting its 309 
potential utility as a marker of response at diagnosis in a real-world clinical setting. 310 
Furthermore, we purposefully used the EULAR criteria as the response measure in this 311 
study as these are universally accepted and encompass both improvement in disease 312 
activity over time and end-point disease activity. Reassuringly, the proportion of 313 
responders in this study is consistent with previous reports using these criteria [44, 52]. 314 
By quantifying methylation at baseline, we are also able to exclude potential 315 
confounding associated with DMARDs, including methotrexate, an impact of which on 316 
methylation has been suggested by several groups [9,10,53,54]. 317 
 318 
Although our proof-of-concept study is the first of its kind in RA, a limitation of our 319 
work was the relatively small number of patients that we were able to recruit. In an 320 
attempt to address this, we used a number of sequential filtering steps to identify sites 321 
differentially methylated between responders and non-responders to treatment. 322 
Furthermore, for the two CpGs comprising the strongest biomarker associated with 323 
response, we validated the array data by also quantifying methylation using an 324 
independent method (Pyrosequencing). This significantly reduces the risk of type I 325 
errors associated with genome-wide approaches. However, we recognise that an 326 
important next step will be to confirm our findings and determine the true predictive 327 
value of this biomarker in larger, independent patient cohorts.   328 
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Conclusions 329 
In conclusion, we report the identification of a novel DNA methylation combination 330 
that is associated with response to treatment with conventional disease-modifying drugs 331 
in newly diagnosed patients with RA. Whilst our findings will require verification in 332 
larger, independent early RA cohorts, they provide the first evidence to support 333 
epigenetic profiling as a novel approach to identifying biomarkers associated with 334 
response to DMARD therapy. Ultimately, this has the potential to inform clinical 335 
management and patient care, towards the goal of a stratified, personalized medicine 336 
approach to treatment.  337 
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Executive Summary 338 
Background 339 
• Newly diagnosed patients with rheumatoid arthritis (RA) demonstrate variability of 340 
response to treatment with disease-modifying antirheumatic drugs (DMARDs).  341 
• To date, no definitive biomarkers associated with response have been identified. 342 
• This proof-of-concept study explored whether DNA methylation at first diagnosis is 343 
associated with response to treatment with DMARDs in patients with treatment-344 
naïve early RA. 345 
Patients & Methods 346 
• HumanMethylation450 BeadChips were used to quantify genome-wide DNA 347 
methylation at diagnosis in T-lymphocytes from 46 treatment-naïve patients with 348 
early RA. 349 
• Response to DMARD treatment was determined at six months using the DAS28-350 
based EULAR response criteria. Sensitivity, specificity and receiver operating 351 
characteristic AUC data were used to assess associations of baseline methylation 352 
with treatment response. 353 
Results 354 
• At six-months, the numbers of patients achieving a good/moderate/no response to 355 
treatment were 16/19/11 (35/41/24%), respectively. 356 
• Array analysis identified 21 CpGs displaying methylation differences between 357 
responders and non-responders, of which four statistically significant sites (padj 358 
<0.05, Bonferroni) showed high sensitivity and/or specificity ≥75% for treatment 359 
response. 360 
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• Methylation at two individual sites in combination (cg0301849 and cg14345882) 361 
was the strongest factor associated with response, with 80.0% sensitivity and 90.9% 362 
specificity (AUC 0.85). 28 of 29 patients with this combination were responders. 363 
Conclusions 364 
• DNA methylation of a novel CpG combination is associated with treatment response 365 
at first diagnosis in early RA patients prior to commencing treatment with 366 
DMARDs. 367 
• These findings provide the first evidence to support epigenetic profiling as a novel 368 
approach to identifying biomarkers associated with DMARD treatment response in 369 
RA. This may ultimately have the potential to inform clinical management and 370 
patient care.  371 
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Figure legends 554 
Figure 1. Filtering criteria for identification of CpGs differentially methylated at 555 
baseline (pre-treatment) between treatment responders and non-responders in 556 
patients with early RA. The starting number of CpGs indicated (482,421) is the total 557 
number of CpGs on the methylation array platform. Following initial processing (step 558 
1), data were normalized using SWAN [35], implemented in the Bioconductor package 559 
Minfi [34]. Numbers in the figure indicate the number of CpGs remaining at each 560 
successive step. 561 
Abbreviations: RA, rheumatoid arthritis; SWAN, subset-quantile within array 562 
normalization. 563 
 564 
Figure 2. Pre-treatment methylation status discriminates responders and non-565 
responders in patients with early RA. In (A) CpG-2 (cg03018489) and (B) CpG-3 566 
(cg14345882), non-responders (n = 11) and responders (n = 35) are depicted by open 567 
circles and filled triangles, respectively, and where responders are divided into those 568 
showing a moderate (centre, n = 19) and good (right, n = 16) response to treatment. 569 
Good, moderate and no response categories are defined in the EULAR response criteria 570 
[23-25]. The horizontal dashed line indicates the methylation cut-off for distinguishing 571 
between responders and non-responders, and the short horizontal bar in each group 572 
indicates the mean value. 573 
Abbreviations: RA, rheumatoid arthritis; EULAR, European League Against 574 
Rheumatism). 575 
 576 
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Figure 3. Pre-treatment methylation status at two CpG sites in combination is 577 
associated with response to treatment in patients with early RA patients. For CpG-578 
2 (cg03018489) and CpG-3 (cg14345882) methylation status was defined as 579 
hypermethylated (above) or hypomethylated (below) relative to a cut-off of 60% and 580 
20%, respectively. Shown on the x-axis are the four possible methylation combinations, 581 
with methylation status of CpG-2 given first and of CpG-3 given second, as indicated 582 
(the two combinations in which only one CpG satisfied the cut-off value are grouped 583 
together (centre chart)). Each chart depicts the proportion of patients achieving a good 584 
(white), moderate (striped) and no response (dark grey) to treatment, stratified by 585 
methylation status for the CpG-2/CpG-3 combination. 586 
Abbreviations: RA, rheumatoid arthritis; Hypo, hypomethylated; Hyper, 587 
hypermethylated. 588 
 589 
Supplementary Figure 1. Technical validation by bisulfite pyrosequencing of 590 
baseline methylation status for two CpGs differentially methylated between 591 
responders and non-responders in patients with early RA. In both (A) CpG-2 592 
(cg03018489) and (C) CpG-3 (cg14345882), responders (n = 35) and non-responders (n 593 
= 11) are depicted by triangles and circles respectively. The short red horizontal bar 594 
shown in each group indicates the mean value. For each CpG, methylation values are 595 
shown for the array (filled symbols; left) and Pyrosequencing (open symbols; right). 596 
Bland-Altman plots in (B) CpG-2 (cg03018489) and (D) CpG-3 (cg14345882) show the 597 
agreement between % methylation levels as determined by 450K array and 598 
pyrosequencing analysis. Each point represents an individual patient. Shown by 599 
horizontal lines are the mean difference between the methods (bias) and the upper and 600 
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lower boundaries of the 95% limits of agreement (± 1.96 SD). The intraclass correlation 601 
coefficient between the methods is 0.963 for CpG-2, and 0.690 for CpG-3. 602 
Abbreviations: RA, rheumatoid arthritis; 450K, HumanMethylation450 BeadChip 603 
 604 
Supplementary Table 1. Assay details for candidate CpGs/genes interrogated by 605 
bisulfite Pyrosequencing.* 606 
*Further information that is not included here is available upon request. 607 
†The prefix 'b-' denotes biotin labeling at the 5' end. 608 
‡The sequence indicated is post-bisulfite conversion. Letters 'Y' and 'R' denote the 609 
cytosine of the CpG site interrogated by the assay ('Y' and 'R' refer to sequencing in the 610 
forward and reverse orientation, respectively). 611 
Abbreviations: bp, base pairs. 612 
 613 
Supplementary Table 2. Baseline demographic and clinical characteristics in early 614 
RA patients who responded and did not respond to DMARD treatment at 6-615 
months follow-up. 616 
* Mann-Whitney U test (continuous variables) or Fisher’s exact test (categorical), as 617 
appropriate. 618 
† data unavailable for two patients. 619 
‡ data unavailable for one patient. 620 
§ 26/45 (57.8%) patients were positive for ACPA/ RF (data unavailable for one patient). 621 
¥ The total number of patients starting treatment with a given DMARD, whether 622 
received as monotherapy or in combination with other DMARDs. 623 
* One further patient received monotherapy with hydroxychloroquine. 624 
33 
 
# One patient was not receiving DMARD treatment. 625 
Abbreviations: RA, rheumatoid arthritis; DMARDs, disease-modifying anti-rheumatic 626 
drugs; RF, rheumatoid factor; ACPA, anti-citrullinated peptide antibodies; DAS28, 627 
disease activity score with 28-joint count; ESR, erythrocyte sedimentation rate. 628 
 629 
Supplementary Table 3. Complete list and annotation for the 21 CpGs identified as 630 
differentially methylated at baseline (pre-treatment) between responders and non-631 
responders in patients with early RA patients.* 632 
*Bold blue font indicates CpGs with statistically significant (p <0.05, Bonferroni-633 
adjusted) differences in methylation between responders and non-responders. The 634 
dashed horizontal line between rows 18 and 19 separates CpGs that were 635 
hypermethylated (above) and hypomethylated (below) in responders relative to non-636 
responders. 637 
†The 'dmpFinder' function in Minfi [34] was used to calculate F-test p-values. 638 
Abbreviations: RA, rheumatoid arthritis. 639 
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Table 1. Demographic and clinical characteristics at baseline for the cohort of 46 
treatment-naïve patients with early RA. 
Number 46 
Male/female, No. (%) 16/30 (34.8/65.2) 
Age, mean ± SD (years) 57.7 ± 13.9 
RF positive, No. (%)†§ 23 (52.3) 
ACPA positive, No. (%)‡§ 22 (48.9) 
DAS28, mean ± SD 5.29 ± 1.4 
ESR, mean ± SD 30.1 ± 23.7 
Corticosteroids, No. (%) 45 (97.8) 
Starting DMARD, No. (%)¥  
     Methotrexate (MTX) 43 (93.5) 
     Hydroxychloroquine (HCQ) 29 (63.0) 
     Sulphasalazine (SSZ) 23 (50.0) 
Starting treatment regimens, No. (%)  
     Monotherapy (MTX)* 15 (32.6) 
     Triple therapy (MTX+HCQ+SSZ) 20 (43.5) 
     Dual therapy (two of MTX, HCQ and SSZ) 10 (21.7) 
† of 44 patients (data unavailable for two patients). 
‡ of 45 patients (data unavailable for one patient). 
§ 26/45 (57.8%) patients were positive for ACPA/ RF (data unavailable for one patient). 
¥ The total number of patients starting treatment with a given DMARD, whether 
received as monotherapy or in combination with other DMARDs. 
* One further patient started monotherapy with hydroxychloroquine. 
646 
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Table 2. Association of baseline methylation status with treatment response in 
patients with early RA.* 
CpG ID 
Methylation 
in responders: 
Hyper/Hypo 
Sensitivity 
(%) 
Specificity 
(%) 
PPV 
(%) 
NPV 
(%) 
ROC AUC 
(95% CI) 
Individual sites       
CpG-1  (cg07225509) Hyper 77.1 72.7 90.0 50.0 0.75 (0.59, 0.86) 
CpG-2  (cg03018489) Hyper 91.4 63.6 88.9 70.0 0.78 (0.64, 0.89) 
CpG-3  (cg14345882) Hypo 88.6 63.6 88.6 63.6 0.76 (0.61, 0.87) 
CpG-4  (cg23974730) Hypo 82.9 63.6 87.9 53.9 0.73 (0.59, 0.86) 
Combinations       
CpG-1 + CpG-2 Hyper/Hyper 71.4 90.9 96.2 50.0 0.81 (0.66, 0.91) 
CpG-1 + CpG-3 Hyper/Hypo 65.7 81.8 92.0 42.9 0.74 (0.59, 0.86) 
CpG-1 + CpG-4 Hyper/Hypo 60.0 90.9 95.5 41.7 0.75 (0.61, 0.87) 
CpG-2 + CpG-3 Hyper/Hypo 80.0 90.9 96.6 58.8 0.85 (0.71, 0.94) 
CpG-2 + CpG-4 Hyper/Hypo 77.1 72.7 90.0 50.0 0.75 (0.59, 0.86) 
CpG-3 + CpG-4 Hypo/Hypo 74.3 90.9 96.3 52.6 0.83 (0.69, 0.92) 
*Of the six CpGs identified as significantly differentially methylated between 
responders and non-responders (see main text), shown are the four CpGs with a 
sensitivity and/or specificity ≥75% and that showed most promise for discriminating 
between responders and non-responders. Also shown are the six possible CpG pairs 
derived from these four sites. All individual sites and combinations shown were 
significantly associated with treatment response (p <0.05, Fisher’s exact test). The CpG-
2 + CpG-3 combination displayed the best overall performance (p <0.001; bold font). 
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